E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Bacterial colonization of peripheral venous catheters |
|
E.1.1.1 | Medical condition in easily understood language |
Bacterial colonization of peripheral venous catheters |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Bacterial Infections and Mycoses [C01] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10069718 |
E.1.2 | Term | Bacterial colonization |
E.1.2 | System Organ Class | 100000004862 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Estimate the incidence of colonization of peripheral venous catheters after disinfection with a 0.5% sodium hypochlorite solution preceded or not by an application of a 70% ethanol solution. |
|
E.2.2 | Secondary objectives of the trial |
Assess the occurrence of local or systemic catheter-related infectious complications after disinfection with 0.5% sodium hypochlorite solution with or without application of 70% ethanol solution.
Assess skin tolerance after disinfection with 0.5% sodium hypochlorite solution with or without application of 70% ethanol solution.
|
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Impact of skin microbiome on infectious and non-infectious complications of peripheral intravenous catheter devices inserted after skin disinfection with DAKIN® alone or preceded by ethanol (KTBiome 2)
Version n°1 du 19.02.2020
Main Objective
Determine the microbial signature to predict the colonization of a peripheral venous catheter, according to the skin disinfection protocol using 0.5% sodium hypochlorite versus 0.5% sodium hypochlorite preceded by ethanol.
Secondary Objectives
- Determine the ecological impact of sodium hypochlorite 0.5%.
- Determine microbial associations to non-infectious adverse events
o Phlebitis.
o Catheter obstruction
o Undesirable symptoms (pain, pruritus, ...)
|
|
E.3 | Principal inclusion criteria |
- Adult patient (≥18 years old) requiring hospitalization in participating services
- Having an indication for the placement of a peripheral venous catheter for an expected duration of at least 48 hours
- Free subject, without guardianship or curatorship or subordination
- A person affiliated to or benefiting from a social security scheme.
- Having given free and informed consent
|
|
E.4 | Principal exclusion criteria |
- Hypersensitivity to any of the constituents of Dakin® and/or Cooper® modified alcohol;
- History of epilepsy,
- Placement of a peripheral venous catheter in the emergency room that does not allow the usual rules of hygiene to be respected;
- Difficult vascular access foreseeable (drug addict, obese, non-visible veins...);
- Participation in another research protocol reducing the risk of catheter-related infection;
- Patient having received an antibiotic treatment in the 15 days prior to inclusion in the study;
- Patient who has already participated in the study;
- Subjects not affiliated with a Social Security system.
- Subjects benefiting from enhanced protection, namely persons deprived of their liberty by a judicial or administrative decision, persons staying in a health or social institution, adults under legal protection (guardianship and trusteeship) and finally patients in emergency situations.
- Pregnant or breastfeeding women, women of child-bearing age who do not have effective contraception (hormonal/mechanical: per os, injectable, transcutaneous, implantable, intrauterine device, or surgical: tubal ligation, hysterectomy, total oophorectomy...). |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Incidence of colonized catheters defined as the culture of the intravascular end of the catheter with at least 1000 colony-forming units per mL (CFU/mL) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The decision to remove the catheter is the responsibility of the patient's physician |
|
E.5.2 | Secondary end point(s) |
- Local infection, defined as colonization of the catheter if removed for suspicion of infection, or purulent discharge at the insertion site with a positive culture or no culture at the insertion site (a negative culture, in the absence of antibiotics, eliminates the case).
- General infection, defined as colonization of the catheter in the presence of general signs of infection (fever > 38.5° or hypothermia < 36°, chills, hypotension with PAS < 90 mmHg) and total or partial regression of these signs within 48 hours after catheter removal.
- catheter-related bacteremia/fungemia, defined as at least one positive peripheral blood culture within 48 hours of catheter removal, associated with general signs of infection (fever > 38.5° or hypothermia < 36°, chills, hypotension with PAS < 90 mmHg) and a catheter culture with the same microorganism (or pus at the site of catheter insertion), with no other infectious focus identified.
- Incidence of a positive catheter culture regardless of the threshold and the microorganism under consideration.
- Incidence of local skin reaction and its severity.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Every day until the catheter is removed |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |